You are here
Efficacy of fesoterodine on nocturia and quality of sleep in Asian patients with overactive bladder
By O. Yokoyama, S. Hiro, S. Hotta, S. Mogami and H. Yamagami.
Urology, Volume 83, Issue 4, April 2014, Pages 750-755
The present article represents a valid example demonstrating that an adequate selection of patients with nocturia, by distinguishing those affected by nocturnal polyuria from those with OAB and reduced bladder capacity, can help to well control the disabling symptom. This is a randomized placebo controlled trial of fesoterodine fumarate 4 and 8 mg once daily in 555 Asian adults affected by OAB with at least ≥ 1 nocturnal micturition/24h. As parameters, changes from baseline to week 12 in frequency of nocturnal voiding, nocturnal urine volume and time of undisturbed sleep have been also examined. It was observed that fesoterodine 4 and 8 mg once daily can be effective in treating nocturia only in patients who did not present with a nocturnal polyuria index >33%. Particularly, in the latter patients’ population, the decrease in nocturnal micturitions was significantly higher with fesoterodine 8 mg vs placebo; fesoterodine 4 mg was able to induce a significant reduction in nocturnal urine volume anda significant amelioration in time of undisturbed sleep, vs placebo. Finally, also sleep energy scores, as evaluated by the King’s Health Questionnaire appeared significantly better.